Corcept Therapeutics Inc
F:HTD
Corcept Therapeutics Inc
F:HTD
Price:
66.58
EUR
2.15%
Market Cap:
€7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently viewed
Price
Economic Moat
Corcept Therapeutics has a wide economic moat
No Moat
Narrow
Wide
Patents covering relacorilant and its use in ovarian cancer make it harder for rivals to copy Corcept’s approved Lifyorli treatment. FDA approval lets Corcept sell it for a defined group of patients, giving the company a protected treatment option in that market.
What protects Corcept Therapeutics from competitors
Intangible Assets
Corcept holds patents covering relacorilant and its use in ovarian cancer, and FDA approval lets it sell Lifyorli for certain patients alongside chemotherapy. The patents make direct copying harder, while the approval allows Corcept to market this treatment for that patient group.
What could weaken Corcept Therapeutics's moat
1 risk to watch
What could happen to the source of the moat and how it would weaken it
